Trials for Cerebellar Ataxias: From Cellular Models to Human Therapies

Author:   Bing-wen Soong ,  Mario Manto ,  Alexis Brice ,  Stefan M. Pulst
Publisher:   Springer International Publishing AG
Edition:   2023 ed.
ISBN:  

9783031243479


Pages:   727
Publication Date:   30 May 2024
Format:   Paperback
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Our Price $517.47 Quantity:  
Add to Cart

Share |

Trials for Cerebellar Ataxias: From Cellular Models to Human Therapies


Overview

Full Product Details

Author:   Bing-wen Soong ,  Mario Manto ,  Alexis Brice ,  Stefan M. Pulst
Publisher:   Springer International Publishing AG
Imprint:   Springer International Publishing AG
Edition:   2023 ed.
ISBN:  

9783031243479


ISBN 10:   3031243471
Pages:   727
Publication Date:   30 May 2024
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Part I: Basic Science of Cerebellum and Ataxias.- Functional anatomy of the cerebellum.- Cerebellar physiology.- Cerebellar biochemistry/pharmacology.- Genetics of dominant ataxias.- Autosomal and X-linked degenerative ataxias: from genetics to promising therapeutics.- Seeking therapies for Spinocerebellar Ataxia: from gene silencing to systems-based approaches.- Ion Channel Genes and Ataxia.- Part II: Biomarkers and tools of trials.- How to Design a Therapeutic Trial in SCAs.- Therapy development for spinocerebellar ataxia: Rating Scales and Biomarkers.- Clinical rating scales for ataxia.- Scale for Ocular motor Disorders in Ataxia (SODA): Procedures and Basic Understanding.- Cerebellar learning in the prism adaptation task.- Blood and CSF biomarkers in autosomal dominant cerebellar ataxias.- Part III: Autosomal Dominant Cerebellar Ataxias.- Riluzole in progressive cerebellar ataxias.- ASOs against ATXN2 in preclinical and phase 1 trials.- Antisense oligonucleotide therapy against SCA3.- Spinocerebellar ataxia type 7: From mechanistic pathways to therapeutic opportunities.- Experimental neurotransplantation for cerebellar ataxias.- Development of mesenchymal stem cells therapy for the treatment of polyglutamine SCA: from bench to bedside.- Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia.- Cerebellar Transcranial Magnetic Stimulation in Cerebellar Ataxias.- Physical therapy in Cerebellar Ataxia.- Part IV: Autosomal Recessive Cerebellar Ataxias.- Recent advances on therapeutic approaches for Friedreich’s Ataxia.- Therapeutic use of interferon gamma in Friedreich ataxia.- Metabolic treatments of cerebellar ataxia.- Clinical Trials in Fragile X-Associated Tremor/Ataxia Syndrome.- Part V: Sporadic Ataxias.- Therapeutic strategies inimmune-mediated cerebellar ataxias.- Coenzyme Q10 in MSA.- State of the Art and History of Therapeutics in Ataxias.

Reviews

Author Information

Bing-wen Soong, MD, Ph.D.  is Professor in Neurology and Genetics (board-certified neurologist and geneticist, certified clinical trial investigator), Taipei Medical University and National Yang Ming Chiao Tung University Faculty of Medicine,  Taipei, Taiwan (Republic of China) Mario Manto, MD, PhD, is the Head of the Department of Neurology at CHU-Charleroi in Belgium. He is also a Professeur de Neuroanatomie et Sémiologie Neurologique, Service des Neurosciences, at UMons, Mons, Belgium. Alexis Brice, MD, Ph.D., is the Executive Director at the Paris Brain Institute in the ICM, Hôpital de la Pitié-Salpêtrière, Sorbonne Université  in France.  Stefan-M. Pulst, M.D., Dr. med, is a Professor and  Chair in the Department of Neurology, at the University of Utah. 

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

NOV RG 20252

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List